Rituximab is noninferior to ocrelizumab in suppressing disease activity in newly diagnosed multiple sclerosis, with a similar incidence of adverse events, a new trial shows.

A noninvasive ultrasound device restored heart rhythm in animal models and engineered human heart cells, paving the way for ...

Once nearly always fatal, pernicious anemia became treatable through a series of discoveries linking the stomach, liver, and ...

Antiamyloid drugs clear amyloid plaques and modestly slow cognitive decline in patients with Alzheimer’s disease, but whether ...

The weight-loss drug is approved to treat obstructive sleep apnea, but some types of patients seem to benefit the most.

An imaging-derived muscle-fat index predicts heart failure, cardiovascular deaths, and all-cause deaths more accurately than BMI and waist-based measures.

Six weeks of sleep restriction increased weight, waist circumference, leptin levels, and time spent inactive in adults with cardiometabolic risk.

In Canada, ED overcrowding, particularly with older adults, is a healthcare system failure that must be addressed across ...

Fascinating nervous system imaging reveals previously unseen obesity-related nerve damage in mice and humans — and some of it ...

New data suggest an approach that could improve the use of guideline-directed medical therapy among patients with heart ...

Data presented at EULAR 2026 confirm that tight disease control can lead to safe pregnancies but also expose a critical need ...

A network meta-analysis of 19 weight-loss drugs concludes that most obesity drugs don’t improve quality of life or cardiovascular health.